¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º S{.G=O  
gxf{/EjH  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ r)Dln5F  
@Fs2J_v  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) NKJ+DD:'  
Wd78 bu|  
1. ICAM-1 y?4% eD  
8n`O{8:fi  
2. interleukin 12(IL-12) ,rZp(moj  
)~CnDk}^R  
3. tumor infiltrating lymphocyte !`$xN~_  
XI"8d.VR  
4. TCR/CD3 complex ,y%4QvG7a  
\ =(r6X  
5. hematopoietin receptor family AIK99  
8kA2.pIk  
6. individual idiotype(IdI) {@tqeu%IM  
sH_5.+,`  
7. integrin Rx,Qw> #  
:<w2j 6V  
8. colony-stimulatory factor (CSF) vC1D}=Fp  
0!6n  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© %4 0uw3  
0[SJ7k19  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? W7 iml|WV0  
\ f6@B:?y  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ hnf7Q l}  
C % d  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷Óᣠ'1u!@=.\G  
CR KuN  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ [@RJ2q$  
=!pfgE  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) gs?=yNL  
H)u<$y!8  
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔ­Àí¡£ h0v4!`PQ-  
V_.n G;  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) +2WvGRC  
wy)I6`v  
3. immunoglobulin superfamily (IgSF) =^L?Sgg  
`EjPy>kM  
4. selectin 'c")]{  
`_*NFv1_  
5. anti-idiotypic antibody (¦ÁId) v\;hI5WY  
`VB]4i}u  
6. major histocompatibility complex(MHC) )X dpzWod  
R,'` A.Kk  
7. immunotolerance Ie14`'  
\4B2%H  
8. biological reponse modifier(BRM) Z\@m_ /g  
F N)vFQ#J  
9. immune reponse gene (Ir gene) 9iWs'M  
/6$8djw  
10. reshaped antibody (or reconstituted antibody)  H%AF,  
#UO#kC<2(B  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© zURob MpE#  
}/{G  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ :mpR}.^hv  
qxR7;/@j)  
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? { 4(E @  
c,\!<4  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ G31??L:<  
z 5T_  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? z g'1T2t  
Ai 9UB=[R  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ =h#3D?b0n  
lQnl6j  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? RH=Tu6i  
?2#v`Z=L;  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡  ?Cu1"bl  
N0D)d  
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ G O=&  
41d,<E  
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? ]lKQ wpX3  
jf_0IE  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ KvFGwq"X  
m}x&]">9  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: e@-"B9~   
3M nm2*\  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: tPT\uD#t  
A1zqm_X5)P  
ÃâÒßѧ &*}NN5Sv  
Qo4+=^(  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© n.[0#Ur&}  
MZ(TST"  
1. CD8 FyZa1%Tv@  
Wp0e?bK_  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) 6z^Kg~a   
%f{1u5+5  
3. immunoglobulin fold(Ig fold) 6AZJ,Q\E@  
He)<S?X-6  
4. cadherin (Ca-dependent cell adhesion moleculers) G;n'c7BV  
y\'t{>U/  
5. idiotype-anti-idiotypic antibody immune network theory O1@-)<_71  
q;T3bxp+  
6. HLA class II antigen TzXivE@mm  
wW3fsXu  
7. complementarity-determining region (CDR) 8{5Y%InL  
uzO%+B!  
8. perforin(or pore-forming protein ,PFP) Wgl7)Xk.)  
YfC1.8  
9. high affinity IL-2 receptor uiO7sf6  
yZ[H&>  
10. artificial active immunization ta>:iQ a  
(+<SR5,/3  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© f>)k<-<yj  
`~Eo;'(+^  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦ÓᣠY{X79Rd   
k zhek >  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 PaF`dnJ  
=,0E]M Z  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ qp*C%U  
y]5O45E0  
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô­¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ R07Kure  
BN&^$1F((  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ ?Kw~O"L8  
Vx@JP93|  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? "d'D:>z]%  
x^kV;^ I  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ <syMrXk)R(  
A-\OB Nh  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ &MnS( 82L  
YaJ[39V  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ oL Eqy  
K_ P08  
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ 1BK-uv:  
tz-, |n0  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© z{U2K '  
LutP&Ebt8  
1. immunoglobulin gene rearrangement 0R&$P 6  
5LU8QHj3  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) ;^nN!KDjR  
g$<Sh.4A  
3. flow cytometry(FCM) 5y;texsj[  
lAU`7uE  
4. carrier effect '+LbFGrO3  
8SII>iL{  
5. positive selection of T lymphocytes in thymus Pu dIb|V2  
XVcY?_AS#  
6. mouse TH1(Th1) and TH2(Th2) subsets {fe[$KQ  
-J8&!S8X  
7. perforin (pore-forming protein ,PFP) U:xY~>  
e E: J  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) U_ ELeW5@  
rM/Ona2x  
9. SH-2(src-homology region 2) K TJm[44  
K*^3FO}JG  
10. Ab2¦Â (internal image) X6I"&yct  
%O] ]La  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© (/TYET_H  
S- {=4b'  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? *Ii_dpJ  
J?VMQTa/+  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? ASA ]7qyO  
0;9X`z J  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦Óᣠ_Q)rI%A2  
-JgN$Sf  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£  WUnz  
FI|jsO 3  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦ÓᣠZ !HQ|')N5  
*K}h >b 1  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) FfEP@$  
{v CB$@/o  
ÃâÒßѧרҵ£º hb@,fgo!Q  
cg`bbZ  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ FFC"rG  
))M!"*  
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? 1nGpW$Gx  
K"fr4xHq  
´«È¾²¡Ñ§×¨Òµ£º =(]yl_  
s>pM+PoGYd  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ e'nhP  
qXF#qS-28  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ y6#AL<W@=  
c+a"sx\  
Ïû»¯×¨Òµ£º k`aHG8 S\  
=[_=y=G  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ uv#."_Va  
I 0vJJP#  
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? 1iLr KA  
^uCZO  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ .:wo AR W!  
sa?Ul)L2  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© W]B75  
ny l[d|pVa  
1. Fas(CD95)/FasL {e]ktj#+{  
pB;8yz=  
2. common chain of cytokine receptor tS[@3h  
"h \ (a<  
3 . TCR/CD3 complex a[ Y\5Ojm  
oVAY}q|wU  
4. negaive selection of thymocytes  I?R?rW  
jt?DogYx  
5. artificial active immune \2#j1/d4  
"K)ue@?  
6. anti-idiotypic Sv>bU4LHf  
'UFPQ  
7. IgSF hd%O\D?  
(k$KUP  
8. Integrin Cj5=UUnO  
qe_qag9  
9. chemokine U$m[{r2M  
W6&mXJ^3L  
10. B7/CD28 d`sIgll&n  
6|10OTVu`  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© w|[{xn^R  
#>_5PdO  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ L)QAI5 o:3  
m#|h22^H  
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ I4Rd2G_  
qBF}-N_  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ c.{t +OR  
fqm-?vy}  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ &:[hUn8jU  
E5Zxp3N  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ Lgrpy  
8T"8C  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ Z_ (P^/  
P.W@5:sD  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© hwi$:[  
xY@<<  
1. B7/CD28 /c!@ H(^)  
a~w l D.P  
2. Th1 subset m~RMe9Qi  
3Bbd2[<W  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© ={B?hjo<-  
[;$9s=:[  
4. antibody affinity maturation 4Ixu%  
UE 1tm  
5. AP-1 :89AYqT"  
ij&T \):d  
6. single chain variable fragment£¨ScFv£© @ayrI]m#>,  
-m_H]<lWZ  
7. NK cell receptor w'&QNm>  
_KAg1Ww  
8. Zinkernagel-Doherty phenomenon zdgSq v  
-^WW7 g`  
9. Ig fold "#=WD  
9PWqoz2c  
10. CD40/CD40L Q)93 +1]  
J9q[u[QZ9O  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© `8b4P>';O'  
FSHC\8siS  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ ANlzF& K  
UY/qI%#L#,  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ 0jMS!"k   
*5q_fO  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ hs?cV)hDS  
vhL/L?NB$  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ f6JC>Np  
6'ia^om  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ p$}1V2h;  
%d2\4{{S  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ \!s0H_RJY  
FSA"U9 w<  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ ` l}+BI`4  
QRlrcauM  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© VD+y4t' ^  
5sguv^;C5  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© E2( {[J  
z1m$8-4  
1.Co-stimulators (or co-stimulating molecules) DRmN+2I  
!z |a+{  
2.NK-kB 3mH(@ -OA  
<BhN mEo)2  
3.Immunoglobulin superfamily @%4tWE  
S|/Za".Gr  
4.antigen-presenting cell (APC) NG\^>.8  
ILMXWw  
5.death domain qZ rv2dT  
O`D,>=[  
6.CCR and CXCR T5? eb"  
v)-:0 f  
7.Lectin (or mitogen) w6@8cNXK  
OpxJiu=W  
8.Clusters of differentiation, CD) 3FE=?Q  
CyV(+KBe_  
9.B7 family 4A\>O?\  
;ep@ )Y  
10.Cytotoxic T lymphocyte, CTL) 6}^6+@LG  
2y@y<38  
11.IL-15 and IL-15 receptor (IL-15R) P#N@W_""YD  
khS >  
12.MHC restriction Nc[[o>/Cb  
`cn}}1Lg]  
13.Affinity-chromatography ODE^;:z !  
Ry4`Q$=:  
14.Cyctosprin A, CsA X2S:"0?7  
y-=YXqj  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) xa$p,_W:'  
^rIe"Kx  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© GZk{tTv  
Hsvu&>[`S  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 P DtLJt$  
:iVEm9pB)  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ o%V%@q H  
yjB.-o('  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ 8CN~o|uN  
gaa;PX  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© sH `(y)`_  
XWNDpL`j5  
ÃâÒßѧרҵ£º [ r;hF  
mjXO}q7  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ N9jSiRJ  
~L ufHbr  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ SXx;- Ws  
`(6g87h  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ }"o,j>IP  
7PG|e#  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) h:l4:{A64  
3,4m|Z2)  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) D8,V'n>L  
l7M![Ur  
1. ADCC(antibody dependent cell-mediated cytotoxicity) R<AT}!mkR  
6nP-IKL  
2. »·æß¾úËØ(cyclosporin) *^_ywqp  
>+8Kl`2sw;  
3. KIR(killer cell inhibitory receptor) }6#u}^gy  
6Lhfb\2?  
4. HLDA(human leucocyte differentiation antigen) 9Vh>ty1|_  
0CFON2I  
5. Interleukin 18(IL-18) Zwxu3R_  
] f< H?  
6. ÕûºÏËØ(integrin) Y]-7T-*+t  
b2p;-rv  
7. Fas/FasL g (:%E  
Wo[*P\8  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) LtIw{* 3  
tH\ aHU[  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) ~+r"% KnG  
]x<`(  
10. Th1/Th2 r"uOf;m  
c4AkH|  
11. »ùÒòÒßÃç(DNAÒßÃç) JVx ,1lth  
1P1"x T  
12. chemokines and chemokine receptor 1O{x9a5Z?O  
8LZmr|/F*  
13. ÃâÒßÄÍÊÜ S_EN,2'e  
K9 tuiD+j  
14. ¹²´Ì¼¤·Ö×Ó 6x$1En  
AO "pm  
15. ËÀÍö½á¹¹Óò(death domain) XKEd~2h<y  
.tny"a&  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) M]JD(  
?-g/hXx;  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? Np?%pB!Q  
F7r!zKXZ  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦ÓᣠP$=BmBq18`  
j(*ZPo>o D  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î J4 Tc q  
GV aIZh<  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ (4WAoye|  
t|ih{0  
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå tAM t7p-  
M-Tjp'=*  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ /I>o6CI  
E>} (r%B  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) XYM 5'  
[1\k'5rp  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ N5SePA\ ,?  
\9 %SR~  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ !ibdw_H  
88GS Bg:YH  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
2+6=? ÕýÈ·´ð°¸:8
°´"Ctrl+Enter"Ö±½ÓÌá½»